Smith & Nephew plc (LON:SN) has been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is GBX 1,452.83 ($18.98).
SN has been the subject of several research reports. HSBC lowered Smith & Nephew to a “hold” rating and increased their price objective for the company from GBX 1,400 ($18.29) to GBX 1,500 ($19.60) in a report on Tuesday, October 16th. Deutsche Bank reissued a “sell” rating on shares of Smith & Nephew in a report on Friday, October 5th. UBS Group reissued a “neutral” rating on shares of Smith & Nephew in a report on Friday, October 26th. Finally, Berenberg Bank increased their price objective on Smith & Nephew from GBX 1,370 ($17.90) to GBX 1,475 ($19.27) and gave the company a “hold” rating in a report on Friday, November 2nd.
LON SN traded up GBX 54.50 ($0.71) on Monday, hitting GBX 1,475 ($19.27). 4,386,355 shares of the stock traded hands, compared to its average volume of 3,250,000. Smith & Nephew has a 12 month low of GBX 1,173 ($15.33) and a 12 month high of GBX 1,442 ($18.84).
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Further Reading: NASDAQ
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.